Avonex Combination Trial in relapsing—remitting MS: rationale, design and baseline data

Abstract

This study provides an innovative model for academic-industry collaborative MS research and will enhance understanding of the utility of combination therapy for RRMS patients with continued disease activity on an established first-line treatment.